N/A
N=469
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Sarcopenia · Non Small Cell Lung Cancer · Malnutrition
Bottom Line
View on ClinicalTrials.gov: NCT05212285 ↗Enrolled (actual)
469
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Progression Free Survival (PFS) — 350; 773 days
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Inbody 570 (Device); JAMAR Dynamometer (Device); CT scan (Radiation)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Fudan University
- Primary completion
- Apr 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression Free Survival (PFS) |
350; 773 | — |
| SECONDARY Overall Survival (OS) |
1319; 402 | — |
Summary
Growing evidence has confirmed that the prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients. Malignant tumors are often associated with weakness and cachexia, leading to less physical activities and worse moods. However, few studies that have attempted to investigate the impact of nutritional status on the prognosis of NSCLC. Existing applications of nutritional scoring systems in early-stage of NSCLC are very limited. Therefore, this study aims to observe the correlation between nutritional status and the prognosis of patients with early-stage NSCLC, to clarify the value in predicting the overall survival rate and progression-free survival rate of NSCLC patients, and to offer evidence for alleviating the social and economic burden of NSCLC.
Eligibility Criteria
Inclusion Criteria
- The patients with non-small cell lung cancer diagnosed by cytology or pathology meet the standards of clinical diagnosis and treatment guidelines for lung cancer of Chinese Medical Association (2018 Edition)
- TNM staging diagnosis of lung cancer meets the stage IA-IIIA
Exclusion Criteria
- Severe heart failure, acute progressive pulmonary inflammation, acute liver and kidney dysfunction in recent 2 weeks
- Incomplete clinical and follow-up data or disagreement or inability to conduct regular follow-up CT imaging evaluation
- A history of other malignant tumors and related tumor chemotherapy within half year, and previous history of radiotherapy
- Unable to walk, fail to complete the walking test, and the risk of fall down
- Unable to complete BIA examination due to pacemaker implantation and other reasons
- Withdraw from the study for any reasons
Data sourced from ClinicalTrials.gov (NCT05212285). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.